JP2012525818A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2012525818A5 JP2012525818A5 JP2012505007A JP2012505007A JP2012525818A5 JP 2012525818 A5 JP2012525818 A5 JP 2012525818A5 JP 2012505007 A JP2012505007 A JP 2012505007A JP 2012505007 A JP2012505007 A JP 2012505007A JP 2012525818 A5 JP2012525818 A5 JP 2012525818A5
- Authority
- JP
- Japan
- Prior art keywords
- gene expression
- expression signal
- tumor
- genes
- random
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 230000014509 gene expression Effects 0.000 claims description 69
- 108090000623 proteins and genes Proteins 0.000 claims description 40
- 206010028980 Neoplasm Diseases 0.000 claims description 38
- 238000000034 method Methods 0.000 claims description 27
- 201000011510 cancer Diseases 0.000 claims description 12
- 238000011272 standard treatment Methods 0.000 claims description 6
- 230000004083 survival effect Effects 0.000 claims description 6
- 238000011282 treatment Methods 0.000 claims description 5
- 230000031018 biological processes and functions Effects 0.000 claims description 4
- 238000001959 radiotherapy Methods 0.000 claims description 4
- 238000012216 screening Methods 0.000 claims description 4
- 206010027476 Metastases Diseases 0.000 claims description 3
- 108700020796 Oncogene Proteins 0.000 claims description 3
- 102000043276 Oncogene Human genes 0.000 claims description 3
- 230000003211 malignant effect Effects 0.000 claims description 3
- 230000009401 metastasis Effects 0.000 claims description 3
- 238000004393 prognosis Methods 0.000 claims description 3
- 238000002512 chemotherapy Methods 0.000 claims description 2
- 230000028993 immune response Effects 0.000 claims description 2
- 238000011248 postoperative chemotherapy Methods 0.000 claims description 2
- 239000003550 marker Substances 0.000 claims 10
- 239000000090 biomarker Substances 0.000 claims 3
- 239000000107 tumor biomarker Substances 0.000 claims 3
- 101150072531 10 gene Proteins 0.000 claims 1
- 241000283690 Bos taurus Species 0.000 claims 1
- 206010006187 Breast cancer Diseases 0.000 claims 1
- 208000026310 Breast neoplasm Diseases 0.000 claims 1
- 241000282472 Canis lupus familiaris Species 0.000 claims 1
- 241000283707 Capra Species 0.000 claims 1
- 241000700198 Cavia Species 0.000 claims 1
- 241000699800 Cricetinae Species 0.000 claims 1
- 206010059866 Drug resistance Diseases 0.000 claims 1
- 241000282326 Felis catus Species 0.000 claims 1
- 241000699694 Gerbillinae Species 0.000 claims 1
- 241001272567 Hominoidea Species 0.000 claims 1
- 241000282412 Homo Species 0.000 claims 1
- 206010061218 Inflammation Diseases 0.000 claims 1
- 108700041567 MDR Genes Proteins 0.000 claims 1
- 241000699670 Mus sp. Species 0.000 claims 1
- 241000283973 Oryctolagus cuniculus Species 0.000 claims 1
- 241001494479 Pecora Species 0.000 claims 1
- 241000700159 Rattus Species 0.000 claims 1
- 241000282887 Suidae Species 0.000 claims 1
- 238000011256 aggressive treatment Methods 0.000 claims 1
- 230000022131 cell cycle Effects 0.000 claims 1
- 230000004663 cell proliferation Effects 0.000 claims 1
- 239000003814 drug Substances 0.000 claims 1
- 229940079593 drug Drugs 0.000 claims 1
- 230000004054 inflammatory process Effects 0.000 claims 1
- 108020004707 nucleic acids Proteins 0.000 claims 1
- 150000007523 nucleic acids Chemical class 0.000 claims 1
- 102000039446 nucleic acids Human genes 0.000 claims 1
- 230000004044 response Effects 0.000 claims 1
- 238000001356 surgical procedure Methods 0.000 claims 1
- 230000005747 tumor angiogenesis Effects 0.000 claims 1
- 210000004881 tumor cell Anatomy 0.000 claims 1
- 239000013610 patient sample Substances 0.000 description 3
- 230000000694 effects Effects 0.000 description 2
- 230000001640 apoptogenic effect Effects 0.000 description 1
- 108700021031 cdc Genes Proteins 0.000 description 1
- 230000030833 cell death Effects 0.000 description 1
- 230000002596 correlated effect Effects 0.000 description 1
- 230000000875 corresponding effect Effects 0.000 description 1
- 230000002757 inflammatory effect Effects 0.000 description 1
- 108020004999 messenger RNA Proteins 0.000 description 1
- 230000001681 protective effect Effects 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US20288109P | 2009-04-16 | 2009-04-16 | |
| US61/202,881 | 2009-04-16 | ||
| PCT/CA2010/000565 WO2010118520A1 (en) | 2009-04-16 | 2010-04-16 | Process for tumour characteristic and marker set identification, tumour classification and marker sets for cancer |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2015215813A Division JP2016073287A (ja) | 2009-04-16 | 2015-11-02 | 腫瘍特性及びマーカーセットの同定のための方法、腫瘍分類、並びに癌のマーカーセット |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2012525818A JP2012525818A (ja) | 2012-10-25 |
| JP2012525818A5 true JP2012525818A5 (enExample) | 2013-05-30 |
Family
ID=42982085
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2012505007A Pending JP2012525818A (ja) | 2009-04-16 | 2010-04-16 | 腫瘍特性及びマーカーセットの同定のための方法、腫瘍分類、並びに癌のマーカーセット |
| JP2015215813A Pending JP2016073287A (ja) | 2009-04-16 | 2015-11-02 | 腫瘍特性及びマーカーセットの同定のための方法、腫瘍分類、並びに癌のマーカーセット |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2015215813A Pending JP2016073287A (ja) | 2009-04-16 | 2015-11-02 | 腫瘍特性及びマーカーセットの同定のための方法、腫瘍分類、並びに癌のマーカーセット |
Country Status (7)
| Country | Link |
|---|---|
| US (1) | US20120040863A1 (enExample) |
| EP (1) | EP2419533A4 (enExample) |
| JP (2) | JP2012525818A (enExample) |
| CN (3) | CN102421920B (enExample) |
| AU (1) | AU2010237568A1 (enExample) |
| CA (1) | CA2758041A1 (enExample) |
| WO (1) | WO2010118520A1 (enExample) |
Families Citing this family (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| MX338883B (es) | 2010-07-27 | 2016-05-04 | Genomic Health Inc | Metodo para usar expresion de gen para determinar el pronostico de cancer de prostata. |
| US20140011701A1 (en) * | 2011-03-14 | 2014-01-09 | National Research Council Of Canada | Prognostic Marker Sets For Prostate Cancer |
| US12130290B2 (en) * | 2016-11-29 | 2024-10-29 | Trustees Of Tufts College | Compositions and methods for diagnosing breast cancer |
| WO2018219342A1 (zh) * | 2017-06-01 | 2018-12-06 | 立森印迹诊断技术有限公司 | 一种印记基因分级模型和诊断方法及其应用 |
| CN110890128B (zh) * | 2018-09-10 | 2024-02-09 | 立森印迹诊断技术（无锡）有限公司 | 一种用于检测皮肤肿瘤良恶性程度的分级模型及其应用 |
| JP7352937B2 (ja) * | 2019-07-19 | 2023-09-29 | 公立大学法人福島県立医科大学 | 乳癌のサブタイプを鑑別又は分類するための鑑別マーカー遺伝子セット、方法およびキット |
| CN115064209B (zh) * | 2022-08-17 | 2022-11-01 | 普瑞基准科技（北京）有限公司 | 一种恶性细胞鉴定方法及系统 |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7955800B2 (en) * | 2002-06-25 | 2011-06-07 | Advpharma Inc. | Metastasis-associated gene profiling for identification of tumor tissue, subtyping, and prediction of prognosis of patients |
| EP1730308A4 (en) * | 2004-03-05 | 2008-10-08 | Rosetta Inpharmatics Llc | CLASSIFICATION OF BREAST CANCER PATIENTS USING A COMBINATION OF CLINICAL CRITERIA AND INFORMATIVE SKILLS |
| MXPA06014116A (es) * | 2004-06-04 | 2007-08-08 | Aviaradx Inc | Identificacion de tumores. |
| EP1777523A1 (en) * | 2005-10-19 | 2007-04-25 | INSERM (Institut National de la Santé et de la Recherche Médicale) | An in vitro method for the prognosis of progression of a cancer and of the outcome in a patient and means for performing said method |
| JP2010524456A (ja) * | 2007-04-16 | 2010-07-22 | イプソゲン | 乳癌に罹患している雌哺乳動物に対する臨床転帰の傾向を評価する方法 |
-
2010
- 2010-04-16 AU AU2010237568A patent/AU2010237568A1/en not_active Abandoned
- 2010-04-16 CN CN201080020971.2A patent/CN102421920B/zh not_active Expired - Fee Related
- 2010-04-16 WO PCT/CA2010/000565 patent/WO2010118520A1/en not_active Ceased
- 2010-04-16 JP JP2012505007A patent/JP2012525818A/ja active Pending
- 2010-04-16 CN CN201510530592.2A patent/CN105132544A/zh active Pending
- 2010-04-16 CN CN201510530687.4A patent/CN105200124A/zh active Pending
- 2010-04-16 EP EP10764018.7A patent/EP2419533A4/en not_active Withdrawn
- 2010-04-16 US US13/263,426 patent/US20120040863A1/en not_active Abandoned
- 2010-04-16 CA CA2758041A patent/CA2758041A1/en not_active Abandoned
-
2015
- 2015-11-02 JP JP2015215813A patent/JP2016073287A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Hannemann et al. | Changes in gene expression associated with response to neoadjuvant chemotherapy in breast cancer | |
| Wu et al. | Research techniques made simple: single-cell RNA sequencing and its applications in dermatology | |
| Klein et al. | A 17-gene assay to predict prostate cancer aggressiveness in the context of Gleason grade heterogeneity, tumor multifocality, and biopsy undersampling | |
| Jayawardana et al. | Determination of prognosis in metastatic melanoma through integration of clinico‐pathologic, mutation, mRNA, microRNA, and protein information | |
| Park et al. | High expression of CX3CL1 by tumor cells correlates with a good prognosis and increased tumor‐infiltrating CD8+ T cells, natural killer cells, and dendritic cells in breast carcinoma | |
| JP2012525818A5 (enExample) | ||
| Akiyoshi et al. | Predicting the response to preoperative radiation or chemoradiation by a microarray analysis of the gene expression profiles in rectal cancer | |
| Alsaleem et al. | A novel prognostic two-gene signature for triple negative breast cancer | |
| CA2904441A1 (en) | Compositions and methods for cancer prognosis | |
| Wang et al. | Comprehensive analysis of PRPF19 immune infiltrates, DNA methylation, senescence-associated secretory phenotype and ceRNA network in bladder cancer | |
| Creighton | A gene transcription signature of the Akt/mTOR pathway in clinical breast tumors | |
| JP2016073287A (ja) | 腫瘍特性及びマーカーセットの同定のための方法、腫瘍分類、並びに癌のマーカーセット | |
| Matchett et al. | Spatial genomics: mapping human steatotic liver disease | |
| Kawaguchi et al. | Gene Expression Signature–Based Prognostic Risk Score in Patients with Primary Central Nervous System Lymphoma | |
| Luo et al. | A prognostic 4-lncRNA expression signature for lung squamous cell carcinoma | |
| Chang et al. | Single-cell multi-stage spatial evolutional map of esophageal carcinogenesis | |
| You et al. | Identification of a RNA-seq based prognostic signature with seven immune-related lncRNAs for lung adenocarcinoma. | |
| Hao et al. | Sentinel lymph node genes to predict prognosis in node-positive melanoma patients | |
| Bing et al. | An integrative model of miRNA and mRNA expression signature for patients of breast invasive carcinoma with radiotherapy prognosis | |
| Sala et al. | Global serum profiling: an opportunity for earlier cancer detection | |
| Baehner et al. | Genomic signatures of cancer: basis for individualized risk assessment, selective staging and therapy | |
| Liu et al. | Identification of cell subpopulations associated with disease phenotypes from scRNA-seq data using PACSI | |
| Peng et al. | Integrative multi-omics analysis reveals the role of toll-like receptor signaling in pancreatic cancer | |
| JP2020523991A (ja) | Ｐｒａｅｇｎａｎｔ転移性乳癌コホートにおける不良アウトカムの予後指標因子 | |
| Meng et al. | Immune implication of FAM83D gene in hepatocellular carcinoma |